Inventiva Contemplates The End Of The Road

The group’s MASH candidate lanifibranor carries hefty sales forecasts but Inventiva might run out of cash before the approval trial reports.  

Roadblock
• Source: Shutterstock

More from Clinical Trials

More from R&D